Sichuan University: all 107 studies

Page 1 of 2. Open to participants first (66), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory NeuroblastomaRecruitingNCT07767630Early Phase 1
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCRecruitingNCT07748325Phase 2
• A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLCNot yet recruitingNCT07692048Phase 1
• Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical StudyNot yet recruitingNCT07665736
• Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical StudyNot yet recruitingNCT07665697
• Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07658872Phase 2
• Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic CancerNot yet recruitingNCT07637786Phase 1
• Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCCRecruitingNCT07519486Phase 2
• Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Not yet recruitingNCT07501169Phase 2
• Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ AdenocarcinomaNot yet recruitingNCT07374250Phase 2
• Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 InjectionNot yet recruitingNCT07362732Early Phase 1
• Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 InjectionNot yet recruitingNCT07332663Early Phase 1
• Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver MetastasesNot yet recruitingNCT07258147Phase 2
• Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized TrialNot yet recruitingNCT07211009Phase 3
• Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal CancerNot yet recruitingNCT07154108Phase 1
• Lateral Positioning for Extubation After AdenotonsillectomyNot yet recruitingNCT07108218Not applicable
• Adjuvant Immunotherapy for Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07067450Not applicable
• The Intensive Nutritional Support in Esophageal Cancer Undergoing Neoadjuvant TherapyNot yet recruitingNCT07067359Not applicable
• Safety & Efficacy of IR-101 in Relapsed/Refractory NeuroblastomaRecruitingNCT07067346Early Phase 1
• Oncolytic Virus in Esophageal Squamous Cell CarcinomaRecruitingNCT07061704Phase 1/2
• High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System LymphomaRecruitingNCT07014943Phase 2
• Application of KRAS Vaccine in the Treatment of KRAS-mutated MalignanciesRecruitingNCT07004244Phase 1
• NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLCNot yet recruitingNCT06966583Phase 1
• A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLCRecruitingNCT06951464Phase 2
• An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung CancerNot yet recruitingNCT06883552Phase 2
• Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung CancerRecruitingNCT06877299Phase 2
• Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）RecruitingNCT06863350Not applicable
• Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLCRecruitingNCT06769971Phase 2
• A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLCRecruitingNCT06769295Phase 2
• Neoantigen Vaccines in Esophageal Squamous Cell CarcinomaRecruitingNCT06675201Phase 2
• Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)RecruitingNCT06610734Phase 2
• Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCCRecruitingNCT06603402Phase 2
• The Effect of Aromatherapy for First Dental Visit PatientsNot yet recruitingNCT06598904Not applicable
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerRecruitingNCT06431685Phase 1
• Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
• Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky TumorsRecruitingNCT06349837Phase 1
• Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLCRecruitingNCT06348797Phase 1
• Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in AdultsRecruitingNCT06347679Not applicable
• Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPCNot yet recruitingNCT06346808Phase 1
• Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy As an Adjuvant Therapy for Pancreatic CancerRecruitingNCT06344156Phase 1
• Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric CancerNot yet recruitingNCT06229197Not applicable
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
• HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal MetastasisNot yet recruitingNCT06213519Phase 2
• Compared Unidirectional Valve Apparatus and Occluding the Non-ventilated Endobronchial Lumen for Lung Collapse.Not yet recruitingNCT06210256Not applicable
• Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow SpectrumNot yet recruitingNCT06210217Early Phase 1
• Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/IIRecruitingNCT06195189Phase 1/2
• Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung CancerRecruitingNCT06121505Phase 2
• Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALLRecruitingNCT06111625Phase 2
• Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid TumorsRecruitingNCT06084286Phase 1
• Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCTNot yet recruitingNCT06075238Phase 2
• MAP-guided Preemptive Therapy of aGvHD by RuxolitinibNot yet recruitingNCT06075225Phase 2
• Immune Reconstitution After Allo-HSCT and BlinatumomabNot yet recruitingNCT06075212
• Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICCNot yet recruitingNCT06033118Phase 1/2
• Dead Mesenchymal Stem Cells for Radiation Lung InjuryRecruitingNCT06021067Phase 1/2
• To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.Not yet recruitingNCT05948449Phase 2
• Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT05900921Phase 2
• Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid MalignanciesRecruitingNCT05807659Phase 2
• Chidamide Prevents Recurrence of High-risk AML After Allo-HSCTRecruitingNCT05682755Phase 1/2
• Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal MetastasesRecruitingNCT05477927Phase 1
• ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingNCT05466318Phase 3
• Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell TransplantationRecruitingNCT05250362Phase 1/2
• A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingNCT05186506Phase 2
• CXCR4 Modified Anti-BCMA CAR T Cells for Multiple MyelomaRecruitingNCT04727008Phase 1
• Dual-targeting HER2 and PD-L1 CAR-T for Solid TumorsRecruitingNCT04684459Early Phase 1
• Personalized DC Vaccine for Postoperative CancerRecruitingNCT04147078Phase 1
• Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung CancerCompletedNCT04012619Phase 1Results posted
• Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC PatientsCompletedNCT03812549Phase 1Results posted
• Ecological Effect of Arginine Dentifrice on Oral MicrobiotaCompletedNCT02988349Not applicableResults posted
• PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung CancerCompletedNCT02793856Phase 1Results posted
• Effect of Intra-cuff Lidocaine and Tetracaine on Tracheal Tube-induced Emergence PhenomenaCompletedNCT00798018Not applicableResults posted
• Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted AnalysisCompletedNCT07549269
• Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell CarcinomaCompletedNCT07488624
• Effects of Spousal Participation in Breastfeeding Interventions at Different Perinatal Stages on Mothers' Coparenting Cognition and Infant Feeding PatternsCompletedNCT07461038Not applicable
• Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLCWithdrawnNCT06732258Phase 1
• Comparative Effect of Clear Aligner Mandibular Advancement and Twin Block Appliances in Class II MalocclusionCompletedNCT06609733
• Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLCActive, not recruitingNCT06477523Phase 1/2
• Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate CancerCompletedNCT06359821Early Phase 1
• Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World DataCompletedNCT06346821
• Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLCActive, not recruitingNCT05765825Phase 2
• Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.Active, not recruitingNCT05615142Phase 1
• MAP-guided Preemptive Therapy of aGvHDStatus unknownNCT05368181Phase 2
• A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCCStatus unknownNCT05317325Phase 1
• Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid TumorsStatus unknownNCT05235607Phase 1
• Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy ProceduresCompletedNCT05076799Phase 3
• The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCCStatus unknownNCT05042336Phase 1/2
• Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus CancerCompletedNCT05023928Phase 1
• ATG-008 Combined With Toripalimab in Advanced Solid TumorsStatus unknownNCT04337463Phase 1/2
• Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionStatus unknownNCT04263870Phase 2
• Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaStatus unknownNCT04156958Phase 2
• Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor ThrombusStatus unknownNCT04069949Phase 1/2
• Ruxolitinib Plus LVP in Patients With R/R ETP-ALLStatus unknownNCT03613428Phase 1/2
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin LymphomaStatus unknownNCT03602131Phase 2
• Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
• A Prospective Study of Monitoring Immune Response in Locally Advanced Cervix CancerStatus unknownNCT03559803Not applicable
• A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC PatientsStatus unknownNCT03373955
• Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCTStatus unknownNCT03336632Phase 2
• GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell LymphomaStatus unknownNCT03154918Phase 2
• Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell LymphomaStatus unknownNCT03151876Phase 2
• Personalized DC Vaccine for Lung CancerStatus unknownNCT02956551Phase 1

← Sichuan University overview and focus areas